Altamira Therapeutics Provides Update on Nasdaq ListingHamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq’s Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company’s listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. The letter stated that the Company is not eligible for any cure period due to the fact that the Company effectuated one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. The Company intends to appeal this determination to a hearing panel (the “Panel”). The hearing request will result in a stay of any suspension or delisting action pending the hearing. There can be no assurance that the Panel will grant the Company’s request for continued listing or that any extension will be granted by the Panel.
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its First Half 2024 Financial Results and Business Update Call on Tuesday, September 24, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts.
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11Hamilton, Bermuda, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, being held virtually and in person on September 9-11, 2024, at Lotte New York Palace Hotel in New York City.
Altamira Therapeutics Provides Business UpdateHamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) --
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy JournalHamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA – May 23, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that highlights from the NASAR clinical trial with Bentrio® nasal spray in seasonal allergic rhinitis (SAR) have been published in video format on the social media channels of Allergy, one of the highest-ranking journals in the field of allergology world-wide. This follows the journal’s publication in April of the peer-reviewed article “AM-301, a barrier-forming nasal spray, versus saline spray in seasonal allergic rhinitis: A randomized clinical trial” which had provided detailed information about this pivotal trial. The video abstract is presented by Sven Becker, MD, the first author of the publication, and it is accessible via:
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its Full Year 2023 Financial Results and Business Update Call on Friday, April 10, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts.
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementHAMILTON, BERMUDA, Dec. 29, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Dec. 29, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced that it received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on December 28, 2023, indicating that the Company has regained compliance with the minimum bid price requirement. As a result, the listing matter has been closed.
Altamira Therapeutics to Host Investor & Business Update Call on December 11thHAMILTON, BERMUDA , Dec. 05, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA--December 5, 2023--Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it will host an Investor and Business Update Call on Monday, December 11, 2023, 8:30 a.m. ET. The presentation will be available via teleconference or webcast with audio and presenter-controlled slides.
Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12thHAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced that it will host its First Half of 2023 Financial Results and Business Update Call on Tuesday, September 12, 2023. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts.
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, being held virtually and in person on September 11-13, 2023, at Lotte New York Palace Hotel in New York City.
Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in ScandinaviaHAMILTON, BERMUDA, July 20, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it has entered into an exclusive agreement with Pharma Nordic AS for the marketing and distribution of Bentrio®, a nasal spray for protection against airborne allergens, in Norway and potentially further Scandinavian countries. The collaboration agreement will allow Pharma Nordic to market and commercialize Bentrio in Norway beginning in the first quarter of 2024, and, subject to meeting certain milestones, also in Sweden, Finland, and Denmark later on.
Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed JournalHAMILTON, BERMUDA, July 17, 2023 (GLOBE NEWSWIRE) -- -Detailed results from house dust mite trial published in Clinical and Translational Allergy-Study demonstrates statistically significant alleviation of nasal symptoms of allergic rhinitis
Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac RegenerationHAMILTON, BERMUDA , July 05, 2023 (GLOBE NEWSWIRE) -- Heqet will test nanoparticles based on Altamira’s OligoPhore delivery platform in the regeneration of damaged heart tissue
Altamira Therapeutics Provides Business UpdateHAMILTON, BERMUDA, Jan. 27, 2023 (GLOBE NEWSWIRE) --
Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid EventHamilton, Bermuda, Nov. 10, 2022 (GLOBE NEWSWIRE) -- • TIDES Europe Event will be held on November 16-18, 2022, in Vienna, Austria• Company Chief Development Officer, Covadonga Pañeda, Ph.D., to present on the advantages of Altamira’s OligoPhoreTM / SemaPhoreTM RNA delivery technology• Dr. Pañeda to discuss the Company’s two proprietary RNA programs, AM-401 and AM-411
Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid RequirementHamilton, Bermuda, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (
NASDAQCYTO), a company dedicated to developing therapeutics that address important unmet medical needs today announced that it has regained compliance with the Nasdaq listing requirements. On November 08, 2022 the Company received a letter from Nasdaq stating that because the Company’s shares had a closing bid price at or above $1.00 per share for a minimum of ten (10) consecutive business days, the Company’s stock had regained compliance with the Minimum Bid Price Requirement for continued listing on Nasdaq, and that the matter is now closed.
Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamira’s Bentrio under Controlled Grass Pollen ExposureHAMILTON, BERMUDA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- • Publication in International Archives of Allergy and Immunology shows rapid onset and long duration of Bentrio’s protective effects in allergic rhinitis sufferers • Mean increase of total nasal symptom score (TNSS) 1.1 points lower vs. no protection, providing clinically meaningful improvement • Mean increase of TNSS 0.4 points lower vs. established powder allergy blocker spray; Bentrio efficacy rated 2x more favorably by patients • Treatment safe and well tolerated
Altamira Therapeutics Announces Reverse Stock SplitHAMILTON, BERMUDA , Oct. 24, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (
NASDAQCYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its Board of Directors has approved a reverse stock split of its common shares at a ratio of 1-for-20. The reverse stock split is expected to become effective at market opening on October 25, 2022, and the shares to begin trading on the split-adjusted basis on the Nasdaq Capital Market under the Company's existing trading symbol "CYTO." The new CUSIP number following the reverse stock split will be G0360L209. The reverse stock split is primarily being effected to regain compliance with the $1.00 minimum bid price requirement for continued listing on NASDAQ.
Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in AustraliaHAMILTON, BERMUDA , Oct. 03, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (
NASDAQCYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its “NASAR” clinical trial with its BentrioTM nasal spray for seasonal allergic rhinitis (SAR) has resumed the enrollment of study participants in Australia as its pollen season is starting up again.
Altamira Therapeutics’ Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal•Independent peer-reviewed study confirms high potential for OligoPhoreTM delivery platform in RNA-based treatments for osteoarthritis •Knock down of JMJD3 gene remarkably mitigated severity of joint degeneration in animal model
